Trend

QS Research · Michael Burry's Scion Capital analyst template · 2006

BECTON DICKINSON & CO (BDX)

As of 2026-11-20 · 12/15 boxes filled from SEC filings and market data

Report price $212.78 (close 2026-11-20)

Conclusion: WATCH

Conviction low · base case +17% · downside -30% · upside +31%

At $212.78 the market is pricing BDX at 3.29x TTM EV/Sales and 15.3x TTM EV/EBITDA, and on FY2026 continuing-operations revenue of $19.5B the same $74.06B enterprise value is about 3.80x, above the 3.72x peer median; the stock sits 3.4% below its 52-week high with a one-year return of 12.2%, while the low-single-digit FY2027 revenue guide suggests much of the recovery is already in the price. The earnings are real but not cheap: the 61.5x GAAP P/E is distorted by $693.0M of restructuring and $450.0M of impairments, and the adjusted 27.8x and operating 27.5x sit against a 5.2% ROIC below a 5.5% WACC, so the call is WATCH. The base case is $248.31, +16.7%, on EV/Sales at 3.72x, the peer median EV/Sales across six peers; the downside is $148.89, -30.0%, on -10.0% sales at a compressed EV/Sales of 2.8x (today 3.29x); the upside is $278.11, +30.7%, on the base case's multiple on +12% earnings.

Key numbers

  • Share price: $212.78
  • Market cap: $57.96B
  • Latest financial period: TTM to Jun 30, 2026
  • Revenue (TTM): $22.48B
  • EV / EBITDA (TTM): 15.3x
  • P/E (TTM): 61.5x
  • Price / book: 2.37x
  • Earnings-quality flags (TTM): Impairments -$450.0M (48% of net income); Restructuring charges -$693.0M (74% of net income)
  • P/E, adjusted (TTM): 27.8x
  • P/E, operating (tax-normalized) (TTM): 27.5x
  • Revenue growth (latest fiscal year): +8.2%
  • ROIC (TTM): 5.2%
  • WACC: 5.5%
  • Economic profit spread: -0.3 pts

The 15 boxes

  1. ✓ 1. Long-form business notes

    BDX's reported base is $16.07B of revenue in FY2020, $21.84B in FY2025 and $22.48B on the TTM to 2026-06-30, with operating income of $912.0M, $2.58B and $2.40B on the same three bases; the TTM net income to common of $942.0M sits far below TTM pre-tax income of $1.88B and TTM operating income of $2.40B, and these sources do not itemize what separates them. Operating cash flow is shown only for FY2020 ($3.54B) and FY2021 ($4.65B), while capital returns have been stepped up to $2.50B of buybacks in the TTM period against $641.0M of cash at FY2025 and $708.0M at the TTM date. The business narrative available is reimbursement and regulatory risk: CMS competitive bidding and China volume-based procurement pressure on price, an amended FDA consent decree plus two warning letters, ethylene oxide sterilization rules, and softer government research funding described in the latest filing.

  2. ✓ 2. Competitive advantage

    BD has scale and distribution reach, but the 10-K describes a fragmented, price/innovation-driven market with low-cost entrants and no single material patent. Revenue was $21.84B in FY2025 and $22.48B in the TTM to 2026-06-30, while operating income was $2.58B in FY2025 but $2.40B in that TTM. The durable advantages look like portfolio breadth, distribution and regulatory capability rather than cost or a single protected product; payer control and competition limit pricing power.

  3. ✓ 3. 10-Q takeaways

    Q3 FY2026 (quarter ended June 30, 2026) revenue rose 5.4% to $4.983B, 4.4% on a foreign currency-neutral basis, but gross margin slipped to 46.4% from 47.3% on tariffs, higher labor costs and El Paso Warning Letter remediation costs. Adjusted diluted EPS from continuing operations rose to $3.23 from $3.08, while GAAP EPS was $1.64 after $437M of after-tax specified items (a $(1.59) per-share drag). Nine-month continuing operating cash flow was $2,104M (up 33.3%) and free cash flow $1.7B, funding $2.250B of buybacks and $875M of dividends while total debt fell to $16,808M. FY2026 guidance was updated on August 6, 2026 to adjusted diluted EPS of $12.62-$12.72 (midpoint raised) with revenue growth toward the high end of a low-single-digit-plus range.

  4. ✓ 4. Corporate governance

    Filled; members read this box.

  5. ✓ 5. Overview of the prior 3 years of 8-K filings

    Filled; members read this box.

  6. ✓ 6. Other significant filings

    Filled; members read this box.

  7. ✓ 7. Chronology of significant news and events

    Filled; members read this box.

  8. ✓ 8. Comparables valuation interpretation

    Filled; members read this box.

  9. ✓ 9. Insider trading interpretation

    Filled; members read this box.

  10. ○ 10. Earnings-call notes
  11. ○ 11. Impression of the shareholder letter
  12. ○ 12. Scuttlebutt overview
  13. ✓ 13. Valuation and risk/reward summary

    Filled; members read this box.

  14. ✓ 14. Current price suppression and potential catalysts

    Filled; members read this box.

  15. ✓ 15. Conclusions

    The call above.

Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.

Put these signals to work

The Scion template's preview is free. Paid members read every box of every report. FST, the QuantSignals trading agent, uses QS Research as its brain.

Join freeMeet FSTSee plans